A B S T R A C T In order to study the splanchnic metabolism of blood-borne estrogens, a constant infusion of estrone-6,7-2H was made in a series of dogs, and arteriovenous (A-V) differences at equilibrium were determined for estrone-6,7-2H and for its products estradiol-17P, estrone estradiol-17,8 by the intestine, associated with substantial net production of estrone glucosiduronate. There is net uptake of estrone by the spleen and a small but significant net uptake of estrone glucosiduronate.
INTRODUCTION
The evident importance of the enterohepatic circulation of estrogens in the human has stimulated considerable investigation into the details of its operation. Thus, a number of studies have been devoted to the nature and origin of estrogen secreted into the bile (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Furthermore, it has recently been shown that estrogens are actively metabolized as they pass through the enterohepatic circulation. For instance, estrogens brought to the intestine via the bile undergo transformations in the intestinal lumen and on passage through the intestinal wall (5, 6, [10] [11] [12] . The transformations have been well documented in the case of estriol conjugates (6, [10] [11] [12] .
However, these studies relate mainly to estrogens within the human enterohepatic circulation. There is virtually no knowledge in any species regarding the immediate metabolism of estrogens brought to the splanchnic area in arterial blood, and the nature and amounts of estrogens released by the splanchnic area into the systemic venous system. We are also largely ignorant of the separate activities of the major splanchnic organs in the metabolism of arterial estrogens and of the nature and relative concentrations of estrogens in the different parts of the splanchnic venous system.
It is therefore clear that an investigation of over-all splanchnic metabolism of arterial estrogens, together with an analysis of the separate activity of intestines and spleen, would be of a great potential value. Appropriate studies in the human have been impeded by the difficulty in approaching the venous sampling sites. An animal model was therefore necessary, and the male dog was chosen. The metabolism of radioactive estrone by this animal was recently investigated in work from this laboratory and found to be similar (within the limits of the investigation) to that in the human, except for the substitution of the product estriol-16a, 17a for the human estriol-16a, 17P (13) . Furthermore, this animal is known to have an enterohepatic circulation for estrogens (14) . Accordingly, constant infusions of estrone-6, 7-8H were set up in a series of male dogs, and simultaneous arteriovenous concentration differences were determined for radioactive estrone and for its products estradiol-17fi, estrone sulfate, estrone glucosiduronate, and estradiol-17,8 glucosiduronate across the splanchnic bed as a whole (artery-hepatic vein), across the intestine (artery-superior mesenteric vein), and across the spleen (arterysplenic vein). In order to relate splanchnic estrone metabolism to over-all estrone metabolism, estrone metabolic clearance rates (MCR) were also estimated.
METHODS
Operative procedure. Mongrel male dogs weighing 14.5-29.9 kg were anaesthetised with i.v. pentobarbital, 25 mg/kg. An intratracheal tube was inserted. A cardiac catheter was passed into the right jugular vein and thence into the hepatic vein under fluoroscopic control. The catheter was passed as far into the liver substance as possible. The position of the catheter tip was checked at intervals by fluoroscopy. The right lobe of the liver was catheterized usually, and the left lobe occasionally. No difference in results relative to the lobe catheterized was observed. Although no studies to determine specifically the effect of pentobarbital anesthesia on splanchnic estrogen metabolism were carried out, the widespread use of this anaesthetic in studies in the dog and its absence of effects on hepatic blood flow (15) and oxygen consumption (16) seemed to justify its use in these experiments without further testing.
A small incision was made in the abdominal wall. A small plastic catheter was inserted into a branch of the superior mesenteric vein draining the small intestine and secured, the tip pointing towards the intestine. A small plastic catheter was also inserted into the splenic vein and secured with its point as near the spleen substance as possible (to avoid reflux from the left gastroepiploic vein). The abdomen was closed leaving the sampling ends of the catheters outside. All three veins (hepatic vein, superior mesenteric vein, and splenic vein) were not necessarily catheterized in the same dog. The femoral artery was catheterized. The left jugular vein was catheterized for introducing the loading dose and infusion. Blood samples (5 ml) were drawn simultaneously from each sampling site into heparinized tubes. Total volume of blood withdrawn was usually 45 ml, or occasionally 60 ml, over a 15-20 min period. No effects due to the withdrawal of this relatively small volume of blood were observed.
Loading dose and infusion of estrone-6,7-'H. Authentic estrone-6,7-3H (see below) was dissolved in 0.1 ml of 95% ethanol, and diluted to 20-30 ml with 0.9% (w/v) saline.
The loading dose (radioactivity approximately 20 jACi, mass approximately 0.15 ng) was given into the left jugular vein as a single injection. The infusion (radioactivity approximately 100 /LCi, mass approximately 0.75 ng) was drawn into a calibrated syringe, which was then inserted into a Harvard constant infusion pump (Harvard Apparatus Co., Inc., Millis, Mass.), connected to the left jugular vein catheter, and administered at a constant rate immediately after the loading dose. Aliquots of loading dose and of infusion were taken for subsequent radioactivity measurement. The whole infusion was administered in 35-45 min. After 20 min of infusion, samples were obtained from catheterized sites as described above at approximately 5-min intervals.
Estrogen standards. Estrone-6,7-3H (stated specific activity 30-50 Ci/mmole) was obtained from New England Nuclear Corp. (Boston, Mass.). Each batch, which was used within 2 months of receipt, was tested at intervals for radiochemical purity using column partition chromatography as already described (17) . Over 96% of the total radioactivity was contained in a chromatographic peak which corresponded exactly to a peak due to authentic nonradioactive estrone (see below) when both radioactive and nonradioactive substances were chromatographed together. On crystallization of a mixture of the radioactive material and authentic nonradioactive estrone, specific activity of crystals and mother liquor corresponded and did not vary significantly on repeated crystallization. Estradiol17p-6,7-3H (stated specific activity 30-50 Ci/mmole) and estrone-6,7-'H sulfate (stated specific activity 10-15 Ci/ mmole) were obtained from New England Nuclear Corp. These substances were used only in recovery experiments. Tests for radiochemical purity were carried out as described above for estrone with similar results. Authentic estrone, estradiol-17p and estrone sulfate standards were obtained from Mann Research Labs. Inc., New York. In each case melting points were in the expected range.
On column partition chromatography approximately 95% of the total fluorescence (see below) of each standard was contained in a single peak in the chromatographic position expected for each substance. Nonradioactive estrone glucosiduronate and estradiol-17p-17-glucosiduronate standards were very kindly given by Dr. A. E. Kellie. The methods of synthesis of these conjugates have been described (18) . On testing >95% of total fluorescence was contained in a single peak after column partition chromatography. Estradiol-17,8-3-glucosiduronate was prepared by sodium borohydride reduction of estrone glucosiduronate.
Flitorometry. Fluorescence was obtained by heating the estrogens with sulfuric acid and was measured as described by Preedy and Aitken (19) .
Radioactivity measurements. Radioactivity was measured by scintillation counting, using a Packard (Model 3000 or 4000 series) scintillation spectrometer (Packard Instrument Co., Downers Grove, Ill.). For estrone, estradiol-17p, and estriol, the conditions (including scintillation fluid) were those previously described (13) . The estrogen conjugates were counted in 0.2 ml of water mixed with 10 ml of dioxane containing 10 Unconjugated estrone and unconjugated estradiol-17#.
The dried extract was partitioned between ether and water. The aqueous phase was saved. The ether extract was dried, re(lissolve(d inl a small amount of stationary phase, and applied to the column partition system of Preedy and Aitken (19) . Chromatography was carried out as described (19) except that only the first two sequential mobile phases were used (13, 19) , to separate estrone and estradiol-17#. Fractions were collected and were analyzed for radioactivity and for the mass of the internal standards, estrone and estradiol-17g.
Estrone sulfate. The aqueous phase previously saved was adjusted to pH 6.0 using 0.1 M acetate buffer and 2 mg of the phenolsulphatase preparation Mylase P (Wallerstein Laboratories) per ml of solution added. The solution was incubated at 37'C for 18 hr. The aqueous phase was then extracted with ether as described above. The aqueous phase was saved. The ether fraction was evaporated and the residue chromatographed as already described for unconjugated estrone and estradiol-17#. Fractions Identification of radioactive unconjugated estrogens. Further identification of the radioactivity peaks presumed due to estrone and estradiol-17,6 both in the unhydrolyzed and the hydrolyzed plasma samples was obtained in the following two ways: (a) demonstration that the specific activity of a mixture of the material forming a radioactive peak with the corresponding nonradioactive estrogen standard did not change significantly after acetylation and rechromatography carried out as already described (13), and (b) demonstration that on crystallization of a mixture of the material forming a radioactive peak and the corresponding nonradioactive estrogen standard the specific activity of crystals and mother liquor were similar and did not change significantly after repeated crystallization (13) .
Identification of radioactive conjugated estrogens. More direct identification of the radioactive conjugates (estrone sulfate, estrone glucosiduronate, and estradiol-17/p glucosiduronate) were carried out as follows. Plasma from artery and from hepatic, superior mesenteric and splenic veins (one sample from each site) was extracted with ether, and the ether fraction discarded. The aqueous phase was made 80% in respect of ethanol and was centrifuged. The following nonradioactive standards were added to the supernatant: estrone sulfate, estrone glucosiduronate, estradiol-17#-3-glucosiduronate, and estradiol-17#-17-glucosiduronate. The dried extract was applied to a Florisil column and eluted successively with 50 ml each of ethyl acetate, ethyl acetate-methanol (1: 1), methanol, and methanol-water (1: 1). In this system estrogen sulfates are eluted in the ethyl acetate-methanol mixture and glucosiduronates in the methanol and methanol-water mixtures.
The ethyl acetate-methanol fraction (sulfates) was dried down, a further estrone sulfate standard was added, and the material was rechromatographed on a celite column using chloroform: n-heptane: t-butanol: 1 Mi NH4OH (150: 75: 25: 300). Aliquots of the fractions containing estrone sulfate were analyzed for radioactivity and mass as already described. The remainder of the material was chromatographed again on Silica Gel G plates with benzene: methyl ethyl ketone: ethanol: water (3: 3: 3: 1) (20) as eluent, with standard estrone sulfate as marker. Radioactivity and mass were again determined. Specific activity of the material did not change significantly after the two chromatographic procedures. An aliquot was treated with Mylase P under conditions already described, and the hydrolysis product identified as estrone, using chromatography, derivative formation, and repeated crystallization as already described.
Material eluted in the methanol and methanol-water fractions (glucosiduronates) from the Florisil column was combined with additional estrone glucosiduronate, estradiol-17U3-3-glucosiduronate, and estradiol-17p-17-glucosiduronate standards and chromatographed with DEAE-Sephadex, using as eluent increasing concentrations of NaCl (0.1-0.2 mole/liter) in water in the form of a linear gradient (21) . This system separates estrone and estradiol-17P glucosiduronates. The specific activity of material forming the estrone glucosiduronate peak was estimated. The material was then subjected to thin-layer chromatography on Silica Gel G plates with benzene: methanol: acetic acid (70: 30: 10) and instant thin-layer chromatography (ITLC) (silica gel impregnated glass fiber sheets, Gelman Instrument Company, Ann Arbor, Mich.) with chloroform: acetone: acetic acid mixtures (75: 25: 5 or 75: 50: 5) as eluent. Specific activities of the material corresponding to estrone glucosiduronate were again determined and did not change significantly after chromatography. The material was then hydrolyzed using Ketodase (as already described), and the hydrolysis product identified as estrone by derivative formation and by repeated crystallization as already described.
The estradiol-17p glucosiduronate zone from the DEAESephadex column contained two adjacent radioactivity peaks.
The smaller peak corresponded with the added estradiol-17,1-17-glucosiduronate standard. The specific activity of this peak was estimated, and the material rechromatographed in the thin-layer systems described above. Specific activity of the material corresponding to estradiol-17p-17-glucosiduronate was determined and was found not to change significantly after chromatography. The larger estradiol-17p glucosiduronate peak corresponded with the estradiol-17p-3-glucosiduronate standard. The material contained in each estradiol-17,p glucosiduronate peak was hydrolyzed separately using Ketodase. The product of hydrolysis in each case was identified as estradiol-17fl by derivative formation and repeated crystallization as already described. Details of the above procedures for identifying estrogen conjugates will be described elsewhere.
Calculation of metabolic clearance rate (MCR) and pcr cent extraction (% extr.). The MCR of estrone was calculated in the usual way (22) using the formula MCR = r/x1, where r is the rate of radioactive estrone infusion (cpm/min), and xi the concentration of arterial radioactive estrone at equilibrium (cpm/ml). This gives the MCR in ml/ min, which can then be converted to ml/min per kg, or liter/ day per m2 (Table I ). The surface area of the dog (m2) was calculated from the weight of the dog by the Meeh-Rubner formula (23) . The per cent extraction = 100 -[V/A] 100, where V is the concentration (cpm/ml) of a radioactive estrogen in a vein and A the concentration (cpm/ml) of the same radioactive estrogen in an artery, when samples are obtained simultaneously.
Statistics. The statistical design consisted of the following two complementary analyses: (a) analysis for regression and (b) analysis for random variation or scatter. To determine the significance of trends related to time, linear regression analysis was carried out on the serial arterial and venous concentrations in each dog, where a series contained more than two observations. The series of per cent extractions in each dog were similarly analyzed. For the analysis for random variation, means (m), standard error of the mean (SEM), and coefficients of variation (C of V = SEM X 100/m) were calculated by standard procedures. For the A-V differences the mean difference (d) and standard error of the mean difference (SEMd) were calculated by the usual methods, and the paired t test used to test the significance of a mean difference. The significance of a mean per cent extraction was estimated by testing the significance of the difference between the mean per cent extraction and zero. A value for P of < 0.03 is taken to indicate "significance." The importance of each form of statistical analysis in the interpretation of the data is brought out in the Discussion section. Table II , together with the per cent extractions. There was a significant mean A-HV difference (12 dogs, 39 samples) for estrone (P < 0.001) and a mean per cent extraction of 85.9 (SEM 1.92), which was significantly different from zero (P < 0.001). The results for estradiol-178 (11 dogs, 26 samples) were similar. There was a significant mean A-HV difference (P < 0.001) and a mean per cent extraction of 88.1 (SEM 3.36), which was significantly different from zero (P < 0.001). small but significant mean A-SPV difference (5 stance. On regression analysis any value for the regresdogs, 15 samples) for estrone glucosiduronate (P < sion coefficient significantly different from zero will in-0.01) and a mean per cent extraction of 12.0 (SEM 3.7) validate the MCR calculation since the concentration at which was also significant (P < 0.01). It is to be noted which the system may eventually stabilize is not known. that the per cent extraction in this instance was positive. Difficulty has been experienced by some workers in obtaining a steady state both of precursor and of products DISCUSSION during the infusion of radioactive estrone and of es-
RESULTS
The necessity for establishing a steady state in the de-tradiol-17p in the human (24) . In the present work there termination of the metabolic clearance rate (MCR) is was no significant linear relationship to time in any of apparent. In particular, there can be no trend with time the series of arterial concentrations from which the MCR in the serial arterial concentrations of the infused sub-was calculated (Tables I and II) . Inspection of the serial arterial estrone concentrations for those dogs in which the MCR was calculated (Table II) indicates considerable variation in some instances. In the absence of significant regression such variation can be considered random and will include possible variation in the experimental system and variation due to the collection and analysis of samples. The coefficient of variation for all MCR values (expressed as liter/day per mi) was found to be 6.8 (Table I ).
This compares with coefficients of variation for estrone MCR of 6.1 (males) and 5.3 (females) found in humans by Longcope, Layne, and Tait (22), 8.1 (males) and 3.6 (females) found by Hembree, Bardin, and Lipsett (24) , and 7.4 and 8.0 for testosterone and A4-androstenedione MCR's in dogs found by Chapdelaine (25) . Thus, the variation observed in the present study is in line with that found by other workers, and our MCR determinations appear valid insofar as they can be tested.
The mean plasma MCR for estrone in our series of male dogs can be compared with those reported for the male human. Mean plasma estrone MCR in nine males reported by Longcope et al. (22) (22) . (A minimal figure only can be given for the human since the splanchnic extraction of estrone in the human is as yet unknown.) In our dogs, red cells contained < 10% of total blood estrone-6, 7-3H, and this was true of both arterial and hepatic venous blood.
A steady state is also required in general if a comparison of simultaneous arterial and venous concentrations is to yield valid information of uptake or release of substances by tissues. This subject has been fully discussed by Zierler (27) . Ideally tissue metabolism, blood flow, arterial, and venous concentrations should all remain constant during the period of observation. However, these parameters can seldom be measured independently, particularly in the case of tissue metabolism. The monitoring of blood flow is obviously desirable but was not considered practicable in the present study. Splanchnic blood flow estimations usually depend on hepatic extraction of dyes such as sulfobromophthalein (BSP). There is good evidence that estrogens depress the hepatic Tm for BSP (28) (29) (30) . Conversely it seemed likely that BSP administration would depress the hepatic extraction of estrogens. In the present study the volume of blood drawn was considered too small to have any significant effect; and since nothing else was done specifically to alter blood flow during arterial and venous sampling, any alterations in the splanchnic flow that may have occurred during the course of the experiments were assumed to be small and random.
As already stated the results of regression analysis of serial arterial and venous concentrations and of per cent extractions in Tables II-IV indicated no relationship to time in the majority of instances. In the few instances where significant regression in the arterial series did occur, it was possible to apply a correction. An arterial sample can be corrected for one transit time through the system before comparison with the simultaneously obtained venous sample (27) . Although transit times through the splanchnic bed of the dog specifically for the various estrogens is not known, the transit time for blood has been measured and is in the range of 30-50 sec (31) . When this correction was applied, only trivial alterations in the observed A-V differences resulted indicating that the transit time of the blood through the splanchnic bed is not a significant factor in interpretation of the A-V differences obtained in the present study.
The variation to be observed in some of the arterial series has been mentioned above. This variation also extends to some of the venous and per cent extraction series (Tables II-IV ). The sources of this variation have already been referred to and in the absence of regression in the vast majority of cases may be considered random. Such variation for all dogs in the appropriate categories is measured as SEMd or SEM (see Statistics). Where "significance" is obtained, the total variation must necessarily be small in relation to the effect (i.e., mean A-V difference, or difference between a mean per cent extraction and zero). Even (25) .
The smaller but significant extraction of estrone sulfate (Table II) means that this conjugate is either excreted from the splanchnic bed, presumably into the bile (7), or further metabolized within the splanchnic bed.
In contrast, the negative A-HV per cent extraction of estrone glucosiduronate (Table II) wise indicates substantial production of this group of conjugates by the splanchnic bed. The relationship (Table II) between the mean A-V differences (ignoring sign) for estrone (2512 cpm, SEMd 399) and for estrone glucosiduronate (896 cpm, SEMd 213) on the one hand, and for estradiol-17# (388 cpm, SEM 49.3) and for estradiol-17fi glucosiduronate (212 cpm, SEM 58.0) on the other, shows that the estrone glucosiduronate released from the splanchnic system into the systemic circulation is a significantly smaller proportion of estrone extracted by the splanchnic system than that in the case of estradiol-17P glucosiduronate and estradiol-17,9, respectively. This presumably indicates that estrone and estradiol-17,8 are metabolized somewhat differently by the splanchnic bed.
The separate activity of two major splanchnic organs, namely the small intestines and the spleen, can be estimated from the data in Tables III and IV . The data in Table III show that the intestine is highly active in the metabolism of blood-borne estrogens, as judged by the uptake of estrone and estradiol-17,8 and the release of estrone glucosiduronate. The mean per cent extraction of estrone (45.3, SEM 2.60) and of estradiol-17p (46.1, SEM 12.9) were similar. Both were considerably lower than the corresponding extraction of the splanchnic bed as a whole. This indicates that further extraction of both substances takes place at some other site within the splanchnic bed. Since the per cent extraction due to the spleen (Table IV) is approximately the same as for the small intestine and since the large intestine is thought to be inactive in estrogen metabolism (35) , the probable site of further estrone and estradiol-17j3 extraction is the liver.
The mean per cent extraction (-30.8, SEM 7.9) for estrone glucosiduronate indicates substantial net production of estrone glucosiduronate by the intestines. The intestines must therefore be a principal site for the formation of estrone glucosiduronate from blood-borne estrone within the splanchnic system. Failure to show significant A-SMV differences for estrone sulfate and estradiol-17,8 glucosiduronate suggests that large quantities of these substances are not taken up or released by the intestine.
In the interpretation of the A-SMV differences, the excretory and absorptive properties of the intestines have to be taken into account, together with the possible effects of the enterohepatic circulation of estrogens previously referred to. The significant uptake of bloodborne estrone and estradiol-17,f could represent excretion into the intestinal lumen rather than metabolism in the intestinal wall. Equally the significant release of estrone glucosiduronate into the superior mesenteric vein could be due to absorption of this substance (or of a precursor) brought to the intestinal lumen via the bile. However, it is unlikely that these two separate processes are involved. The experiments were designed to be short-term specifically in order to exclude effects due to the enterohepatic circulation. Thb duration of the experiments (30-45 min) would hardly allow enough time for the formation of conjugates, transfer into the bile, transport to the intestinal lumen, further metabolism, and transfer into the superior mesenteric vein. This process is thought to take about 6 hr in the human (1, 2) . A single explanation is both simpler and more obvious, namely, that arterial plasma estrone and estradiol-17p are taken up by the intestine and metabolized, resulting in the formation of estrone glucosiduronate by intestinal tistsue. The intestinal wall is known to have the capacity to conjugate estrogens with glucuronic acid, but this has so far been shown only for estrogens introduced into the intestinal lumen (6, 11, (33) (34) (35) (36) (37) (38) .
A different pattern in estrogen metabolism is seen in the spleen (Table IV) . There was again uptake of estrone (mean per cent extraction 35.0, SEM 38) which was of the same order as that by the intestine, but less than that of the splanchnic bed as whole. However, in contrast to the intestines and the splanchnic bed as a whole, there was a small but significant uptake of estrone glucosiduronate (mean extraction 12%, SEM 3.7). Since excretion is not possible, the most likely explanation is that the spleen metabolizes small quantities of estrone glucosiduronate by hydrolysis. This organ is known to contain substantial amounts of P-glucuronidase activity in various animal species (39) .
The splanchnic metabolism of blood-borne estrogens in the dog is complex in terms of the number of the major splanchnic organs involved and in the different patterns of activity exhibited. The contribution of each organ to over-all splanchnic metabolism must depend upon relative blood flow through that organ, as well as on the A-V difference. Venous drainage from the intestine accounts for about 60% of the blood flow through the portal vein in the dog and is approximately 12% of the cardiac output (40) . These figures taken with the values for uptake of arterial estrone and estradiol-17fi and release of estrone glucosiduronate gives some indication of the quantitative potential of the intestine in estrogen metabolism. Venous drainage from the spleen accounts for only about 10% of the portal venous flow and is approximately 2% of the cardiac output (40) . Nevertheless, the demonstration of uptake of estrone and of estrone glucosiduronate indicates that the spleen plays some role in splanchnic estrogen metabolism, which could assume importance in certain circumstances. It seems possible that in those forms of human liver disease where liver function is insufficient and the enterohepatic circulation of estrogens is impaired, but where collateral venous circulation allows adequate venous drainage from the intestine and spleen (e.g., in hepatic cirrhosis), the intestine, with the spleen, could take over the greater part of splanchnic estrogen metabolism.
